Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00527124 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

57

Enrollment

NIH

Sponsor class

Stopped Closure was recommended by CTEP due to slow accrual.

Conditions

Adenocarcinoma of the Prostate
Stage IV Prostate Cancer

Interventions

DRUG: cediranib maleate
DRUG: docetaxel
DRUG: prednisone
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)